CEL SCI CORPCVMEarnings & Financial Report
NYSE · Health Care · Biological Products, (No Diagnostic Substances)
CEL SCI Corp is a clinical-stage biotechnology company specializing in developing immunotherapy products for treating cancer and infectious diseases. Its lead pipeline candidate targets head and neck cancer, with clinical trials run across North America, Europe and Asia to evaluate safety and efficacy for global patient groups.
Revenue
$159.1K
Gross Profit
N/A
Operating Profit
$-8.2M
Net Profit
$-8.3M
Gross Margin
N/A
Operating Margin
-5140.3%
Net Margin
-5245.0%
YoY Growth
158.1%
CEL SCI CORP Q2 FY2023 Financial Summary
CEL SCI CORP reported revenue of $159.1K (up 158.1% YoY) for Q2 FY2023, with a net profit of $-8.3M (up 15.1% YoY) (-5245.0% margin).
Key Financial Metrics
| Total Revenue | $159.1K |
|---|---|
| Net Profit | $-8.3M |
| Gross Margin | N/A |
| Operating Margin | -5140.3% |
| Report Period | Q2 FY2023 |
CEL SCI CORP Quarterly Revenue & Net Profit History
CEL SCI CORP results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $-87.8K | +48.4% | $-5.5M | 6230.2% |
| Q3 FY2023 | $-181.7K | +80.1% | $-8.4M | 4605.8% |
| Q2 FY2023 | $159.1K | +158.1% | $-8.3M | -5245.0% |
| Q1 FY2023 | $-152.8K | +44.0% | $-7.9M | 5140.1% |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q1 2026 | |
|---|---|---|---|---|
| Revenue | $-152789 | $159063 | $-181670 | $-87789 |
| YoY Growth | 44.0% | 158.1% | 80.1% | 48.4% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q1 2026 | |
|---|---|---|---|---|
| Assets | $44.6M | $38.2M | $32.3M | $22.9M |
| Liabilities | $18.0M | $18.0M | $17.5M | $11.8M |
| Equity | $26.6M | $20.1M | $14.8M | $11.1M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q1 2026 | |
|---|---|---|---|---|
| Operating CF | $-4.7M | $-7.5M | $-5.7M | $-4.0M |